Moderna shares fell 3% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine. Moderna was awarded the ...

Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.

Moderna shares fell more than 5% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine.

U.S. President Donald Trump claimed on Tuesday that U.S. banks are not allowed to do business in Canada, while their banks ...

Moderna's COVID sales have been declining ... and definitively improve its top line. The one wild card is the personalized cancer vaccine it is developing with Merck. But that's not guaranteed ...

The Trump administration is reconsidering a $590 million human bird flu vaccine contract with Moderna. ( The Hill) Over 40% ...

The facility is the centrepiece of a 10-year agreement-in-principle between the biotech and the UK government – which has been rumoured to be on the cards ... of Moderna’s COVID-19 vaccine ...

Snowflake shares are jumping nearly 11% after the data-software company’s [fiscal fourth-quarter revenue topped estimates]( ...

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple effect is already being felt across biopharma.

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in ...